Close Menu

You may find more results for this query on our sister sites: GenomeWeb and 360Dx.

Home › Business, Policy & Funding › Business News › Resolution Bioscience, Mirati Therapeutics Sign Companion Diagnostic Agreement

Resolution Bioscience, Mirati Therapeutics Sign Companion Diagnostic Agreement

Jan 11, 2021
|
staff reporter

NEW YORK – Resolution Bioscience said on Monday that it has signed a companion diagnostic agreement with San Diego-based Mirati Therapeutics.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

May
26
Featured Webinar

CaTCH it if you can! CRISPRa-based Exploration of Therapy Resistant Cell Clones

Sponsored by
Lexogen

The emergence of cell clones that are resistant to targeted therapies poses a significant issue in the treatment of metastatic melanoma.

What's Popular?

In Molecular Diagnostics

  1. With Support From Lawmakers, WGS Becoming More Accessible to Netherlands' Cancer Patients

    Premium

  2. Survey of Canadian Cancer Centers Sheds Light on Inequities in Biomarker Test Access

    Premium

  3. AACR Study Tests Immunogenic Signature in Prostate Cancer Patients on Dual Checkpoint Inhibitor

  4. Invitae Acquiring Genosity for $200M; Investment Group Provides Firm $1.15B in Senior Notes

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.